Tags

Type your tag names separated by a space and hit enter

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
World J Biol Psychiatry 2010; 11(2 Pt 2):208-19WJ

Abstract

Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the principal psychoactive constituent of the Cannabis sativa plant, and other agonists at the central cannabinoid (CB(1)) receptor may induce characteristic psychomotor effects, psychotic reactions and cognitive impairment resembling schizophrenia. These effects of Delta(9)-THC can be reduced in animal and human models of psychopathology by two exogenous cannabinoids, cannabidiol (CBD) and SR141716. CBD is the second most abundant constituent of Cannabis sativa that has weak partial antagonistic properties at the CB(1) receptor. CBD inhibits the reuptake and hydrolysis of anandamide, the most important endogenous CB(1) receptor agonist, and exhibits neuroprotective antioxidant activity. SR141716 is a potent and selective CB(1) receptor antagonist. Since both CBD and SR141716 can reverse many of the biochemical, physiological and behavioural effects of CB(1) receptor agonists, it has been proposed that both CBD and SR141716 have antipsychotic properties. Various experimental studies in animals, healthy human volunteers, and schizophrenic patients support this notion. Moreover, recent studies suggest that cannabinoids such as CBD and SR141716 have a pharmacological profile similar to that of atypical antipsychotic drugs. In this review, both preclinical and clinical studies investigating the potential antipsychotic effects of both CBD and SR141716 are presented together with the possible underlying mechanisms of action.

Authors+Show Affiliations

Research Group Clinical and Experimental Psychopathology, Department of General and Social Psychiatry ZH West, Psychiatric University Hospital Zurich, Zurich, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20218784

Citation

Roser, Patrik, et al. "Potential Antipsychotic Properties of Central Cannabinoid (CB1) Receptor Antagonists." The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, vol. 11, no. 2 Pt 2, 2010, pp. 208-19.
Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry. 2010;11(2 Pt 2):208-19.
Roser, P., Vollenweider, F. X., & Kawohl, W. (2010). Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, 11(2 Pt 2), pp. 208-19. doi:10.3109/15622970801908047.
Roser P, Vollenweider FX, Kawohl W. Potential Antipsychotic Properties of Central Cannabinoid (CB1) Receptor Antagonists. World J Biol Psychiatry. 2010;11(2 Pt 2):208-19. PubMed PMID: 20218784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. AU - Roser,Patrik, AU - Vollenweider,Franz X, AU - Kawohl,Wolfram, PY - 2010/3/12/entrez PY - 2010/3/12/pubmed PY - 2010/6/15/medline SP - 208 EP - 19 JF - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry JO - World J. Biol. Psychiatry VL - 11 IS - 2 Pt 2 N2 - Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the principal psychoactive constituent of the Cannabis sativa plant, and other agonists at the central cannabinoid (CB(1)) receptor may induce characteristic psychomotor effects, psychotic reactions and cognitive impairment resembling schizophrenia. These effects of Delta(9)-THC can be reduced in animal and human models of psychopathology by two exogenous cannabinoids, cannabidiol (CBD) and SR141716. CBD is the second most abundant constituent of Cannabis sativa that has weak partial antagonistic properties at the CB(1) receptor. CBD inhibits the reuptake and hydrolysis of anandamide, the most important endogenous CB(1) receptor agonist, and exhibits neuroprotective antioxidant activity. SR141716 is a potent and selective CB(1) receptor antagonist. Since both CBD and SR141716 can reverse many of the biochemical, physiological and behavioural effects of CB(1) receptor agonists, it has been proposed that both CBD and SR141716 have antipsychotic properties. Various experimental studies in animals, healthy human volunteers, and schizophrenic patients support this notion. Moreover, recent studies suggest that cannabinoids such as CBD and SR141716 have a pharmacological profile similar to that of atypical antipsychotic drugs. In this review, both preclinical and clinical studies investigating the potential antipsychotic effects of both CBD and SR141716 are presented together with the possible underlying mechanisms of action. SN - 1814-1412 UR - https://www.unboundmedicine.com/medline/citation/20218784/Potential_antipsychotic_properties_of_central_cannabinoid__CB1__receptor_antagonists_ L2 - http://www.tandfonline.com/doi/full/10.3109/15622970801908047 DB - PRIME DP - Unbound Medicine ER -